---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-24-000083"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:28:43.446449+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint

## Summary
- Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.
- No serious adverse events; common AEs mild: headache (50%), nausea (36.4%), crying (27.3%), fatigue (27.3%).
- Mean CAPS-5 total score reduced 29.9 points at week 4 and 29.5 points at week 12 from baseline of 47.5.
- Response rate (≥15-point CAPS-5 improvement) 81.8% at week 4 and 77.3% at week 12; remission rate 63.6% at week 4.
- No patient withdrawals and no return to antidepressant medication during the 12-week study.

## SEC filing metadata
- accession: 0001816590-24-000083
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/0001816590-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/cmps-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-24-000083
- JSON: https://secwatch.observer/filing/0001816590-24-000083.json
- Plain text: https://secwatch.observer/filing/0001816590-24-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.